NASDAQ:IDXX - IDEXX Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$191.76 -1.76 (-0.91 %)
(As of 11/20/2018 03:19 PM ET)
Previous Close$193.52
Today's Range$189.01 - $194.05
52-Week Range$151.74 - $256.22
Volume26,630 shs
Average Volume664,371 shs
Market Capitalization$17.36 billion
P/E Ratio58.87
Dividend YieldN/A
Beta0.82
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
Previous Symbol
CUSIP45168D10
Phone207-556-0300

Debt

Debt-to-Equity RatioN/A
Current Ratio0.93
Quick Ratio0.69

Price-To-Earnings

Trailing P/E Ratio58.87
Forward P/E Ratio45.77
P/E Growth2.55

Sales & Book Value

Annual Sales$1.97 billion
Price / Sales8.40
Cash Flow$4.1194 per share
Price / Cash46.55
Book Value($0.62) per share
Price / Book-309.29

Profitability

EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins15.19%
Return on Equity-994.76%
Return on Assets23.09%

Miscellaneous

Employees7,600
Outstanding Shares86,230,000
Market Cap$17.36 billion
OptionableOptionable

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has approved a stock buyback plan on Sunday, June 4th 2017, which permits the company to repurchase 3,000,000 shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Thursday, November, 1st. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.97 by $0.08. The business earned $545 million during the quarter, compared to the consensus estimate of $545.66 million. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The firm's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.76 earnings per share. View IDEXX Laboratories' Earnings History.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY19 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $4.61-$4.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.83. The company issued revenue guidance of $2.385-$2.425 billion, compared to the consensus revenue estimate of $2.45 billion.IDEXX Laboratories also updated its FY 2017 guidance to $4.61-4.75 EPS.

What price target have analysts set for IDXX?

6 equities research analysts have issued twelve-month target prices for IDEXX Laboratories' shares. Their forecasts range from $235.00 to $260.00. On average, they expect IDEXX Laboratories' share price to reach $248.00 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

What is the consensus analysts' recommendation for IDEXX Laboratories?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Has IDEXX Laboratories been receiving favorable news coverage?

Headlines about IDXX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IDEXX Laboratories earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
  • Mr. Jay Mazelsky, Exec. VP (Age 57)

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.26%), Bamco Inc. NY (4.83%), Renaissance Technologies LLC (2.06%), Neuberger Berman Group LLC (1.82%), Blair William & Co. IL (1.78%) and Bank of New York Mellon Corp (1.26%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., Bamco Inc. NY, Wells Fargo & Company MN, Mitsubishi UFJ Trust & Banking Corp, Banco Santander S.A., TIAA CREF Investment Management LLC and Prudential Financial Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Rehmann Capital Advisory Group, Franklin Resources Inc., State Treasurer State of Michigan, Panagora Asset Management Inc., Kornitzer Capital Management Inc. KS, Rathbone Brothers plc and FMR LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $191.76.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $17.36 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is http://www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  380 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel